CompanyTLSANasdaqLondon, England, X0

Tiziana Life Sciences LTD

Tiziana Life Sciences develops intranasal immunotherapies using alternative drug delivery technologies.

SEC EDGAR ClinicalTrials.gov tizianalifesciences.com

6-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Tiziana Life Sciences seeks FDA orphan drug status for foralumab in MSA

Sep 30Regulatory milestoneforalumab Tiziana Life Sciences LTD

Tiziana doses first ALS patients with intranasal foralumab in BANYAN trial

Sep 28Trial updateforalumab Tiziana Life Sciences LTD

Tiziana completes last patient visit in Phase 2a INFORM-MS foralumab trial

Sep 21Clinical readoutforalumab Tiziana Life Sciences LTD

August 2026

Tiziana presents BANYAN trial poster on intranasal foralumab in ALS at conference

Aug 24Clinical readoutforalumab Tiziana Life Sciences LTD

Tiziana CEO Elrifi buys more shares on two dates in August 2026

Aug 6PeopleTiziana Life Sciences LTD

July 2026

Tiziana registers Phase 2a "BANYAN" trial of nasal foralumab in ALS

Jul 7Trial updateforalumab Tiziana Life Sciences LTD